Fibrinogen Bastia (γ 318 Asp → Tyr) a Novel Abnormal Fibrinogen Characterized by Defective Fibrin Polymerization

Karim Chabane Lounes; Claudine Soria; Antoine Valognes; Marie France Turchini; Jeannette Soria; Jaap Koopman

doi:10.1055/s-0037-1614892

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1999; 82(06): 1639-1643
DOI: 10.1055/s-0037-1614892

Rapid Communication

Schattauer GmbH

Fibrinogen Bastia (γ 318 Asp → Tyr) a Novel Abnormal Fibrinogen Characterized by Defective Fibrin Polymerization

Authors

Karim Chabane Lounes

¹From the Laboratoire Sainte Marie, Hôpital Hôtel-Dieu, Paris

²Laboratoire Difema, Faculté de Medecine et de Pharmacie, Rouen
Claudine Soria

²Laboratoire Difema, Faculté de Medecine et de Pharmacie, Rouen

³INSERM U.153, Hôpital Saint Louis, Paris
Antoine Valognes

⁴Laboratoire du Centre Hospitalier, Bastia, Corse
Marie France Turchini

⁴Laboratoire du Centre Hospitalier, Bastia, Corse
Jeannette Soria

¹From the Laboratoire Sainte Marie, Hôpital Hôtel-Dieu, Paris

⁵Laboratoire de Biochimie A, Hôtel-Dieu, Paris, France
Jaap Koopman

⁶TNO-PG, Gaubius Laboratory, Leiden, The Netherlands

⁷Pharming, Leiden, The Netherlands

Abstract

Summary

A new congenital dysfibrinogen, Fibrinogen Bastia, was discovered in a 20-year-old woman with no clinical symptoms. The plasma thrombin-clotting time was severely prolonged. The functional plasma fibrinogen concentration was low (0.2 mg/ml), whereas the immunological concentration was normal (2.9 mg/ml). Purified fibrinogen Bastia displayed a markedly prolonged thrombin-clotting time related to a delayed thrombin-induced fibrin polymerization. Both the thrombin-clotting time and the fibrin polymerization were partially corrected by the addition of calcium ions. The anomaly of fibrinogen Bastia was found to be located in the γ-chain since by SDS-PAGE performed according to the method of Laemmli two γ-chains were detected, one normal and one with an apparently lower molecular weight. Furthermore, analysis of plasmin degradation products demonstrated that calcium ions only partially protect fibrinogen Bastia γ-chain against plasmin digestion, suggesting that the anomaly is located in the C-terminal part of the γ-chain. Sequence analysis of PCR-amplified genomic DNA fragments of the propositus demonstrated a single base substitution (G → T) in the exon VIII of the γ chain gene, resulting in the amino acid substitution 318 Asp (GAC) → Tyr (TAC). The PCR clones were recloned and 50% of them contained the mutation, indicating that the patient was heterozygous. These data indicate that residue Asp 318 is important for normal fibrin polymerization and the protective effect of calcium ions against plasmin degradation of the C-terminal part of the γ-chain.

Key Words

Fibrinogen - dysfibrinogenemia - plasmin degradation products - fibrin polymerization

Full Text

References

References
1 Olexa SA, Budzynski AZ. Evidence for four different polymerization sites involved in human fibrin formation. Proc Natl Acad Sci USA 1980; 77: 1374-8.
2 Shimizu A, Nagel GM, Doolittle RF. Photoaffinity labeling of the primary fibrin polymerization site: isolation and characterization of a labeled cyanogen bromide fragment corresponding to γ-chain residues 337-379. Proc Natl Acad Sci USA 1992; 89: 2888-92.
3 Spraggon G, Everse SJ, Doolittle RF. Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. Nature 1997; 389: 544-62.
4 Everse SJ, Spraggon G, Veerapandian L, Riley M, Doolittle RF. Crystal structure of fragment double-D from human fibrin with two different bound ligands. Biochemistry 1998; 37: 8637-42.
5 Hardy JJ, Carrell NA, McDonagh J. Calcium ion functions in fibrinogen conversion to fibrin. Ann NY Acad Sci 1983; 408: 279-87.
6 Nieuwenhuizen W, Van Ruijven-Vermeer IA, Nooijen WJ, Vermond A, Haverkate F, Hermans J. Recalculation of calcium-binding properties of human and rat fibrin(ogen) and their degradation products. Thromb Res 1981; 22: 653-7.
7 Dang CV, Ebert RF, Bell WR. Localization of a fibrinogen calcium binding site between g-subunit positions 311 and 336 by terbium fluorescence. J Biol Chem 1985; 260: 9713-9.
8 Nieuwenhuizen W, Haverkate F. Calcium-binding regions in fibrinogen. Ann NY Acad Sci 1983; 408: 92-6.
9 Haverkate F, Timan G. Protective effect of calcium in the plasmin degradation of fibrinogen and fibrin product D. Thromb Res 1977; 10: 803-12.
10 Côté HCF, Lord ST, Pratt KP. γ-chain dysfibrinogenemias: molecular structure-function relationships of naturally occurring mutations in the γ-chain of human fibrinogen. Blood 1998; 92: 2195-12.
11 Rupp C, Kuyas C, Häeberli A, Furlan M, Perret BA, Beck EA. In: Fibrinogen. Henschen A, Graeff H, Lottspeich F. eds. Berlin: Walter de Gruyter; 1982: 167-81.
12 Soria J, Soria C, Samama M, Tabori S, Kehl M, Henschen A, Nieuwenhuizen W, Rimon A, Tatarski I. Fibrinogen Haifa: fibrinogen variant with absence of protective effect of calcium on plasmin degradation of gamma chains. Thromb. Haemost 1987; 57: 3103. Thromb Haemost 1987 Jun 3: 57 (3) 310-3.
13 Koopman J, Haverkate F, Briet E, Lord ST. A congenitally abnormal fibrinogen (Vlissingen) with a 6-base deletion in the gamma-chain gene causing defective calcium binding and impaired fibrin polymerization. J Biol Chem 1991; 266: 13456-61.
14 Yoshida N, Hirata H, Morigami Y, Imaoka S, Matsuda M, Yamazumi K, Asakura S. Characterization of an abnormal fibrinogen Osaka V with the replacement of γ-arginine 375 by glycine. The lack of high affinity calcium binding to D-domain and the lack of protective effect of calcium on fibrinolysis. J Biol Chem 1992; 267: 2753-9.
15 Blombäck B, Blombäck M. Purification of human and bovine fibrinogen. Arkiv. Kemi 1956; 10: 415-43.
16 Caen JP, Larrieu MJ, Samama M. L’hemostase. Methodes d’exploitation et diagnostic pratique. Expanssion scientifique; Paris: 1975
17 Clauss A. Gerinnungsphysiologishe Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol (Basel) 1957; 17: 237-46.
18 Soria J, Soria C, Borg JY, Mirshahi M, Piguet H, Tron P, Fessard C, Caen J. Platelet aggregation occurs in congenital afibrinogenemia despite the absence of fibrinogen or its fragments in plasma and platelets, as demonstrated by immunoenzymology. Br J Haematol 1985; 60: 503-14.
19 Schwartz ML, Pizzo SV, Hill RL, Mc Kee PA. The effect of fibrin-stabilizing factor on the subunit structure of human fibrin. J Clin Invest 1971; 50: 1506-13.
20 Weber K, Osborn M. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem 1969; 244: 4406-12.
21 Laemmli UK. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
22 Rixon MW, Chung BW, Davie EW. Nucleotide sequence of the gene for the γ-chain of human fibrinogen. Biochemistry 1985; 24: 2077-86.
23 Yoshida N, Terukina S, Okuma M, Moroi M, Aoki N, Matsuda M. Characterization of an apparently lower molecular weight γ-chain variant in fibrinogen Kyoto I. The replacement of γ-asparagine 308 by lysine which causes accelerated cleavage of fragment D₁ by plasmin and the generation of a new plasmin cleavage site. J Biol Chem 1988; 263: 13848-56.
24 Miyata T, Furukawa K, Iwanaga S, Takamatsu J, Saito H. Fibrinogen Nagoya, a replacement of glutamine-329 by arginine in the γ-chain that impairs the polymerization of fibrin monomers. J Biochem 1989; 105: 10-4.
25 Terukina S, Yamazumi K, Okamoto K, Yamashita H, Ito Y, Matsuda M. Fibrinogen Kyoto III: a congenital dysfibrinogen with a g aspartic acid-330 to tyrosine substitution manifesting impaired fibrin monomer polymerization. Blood 1989; 74: 2681-7.
26 Ebert RF, Bell WR. Fibrinogen Baltimore III. Congenital dysfibrinogenemia with a shortened g-subunit. Throm Res 1988; 51: 251-8.
27 Yoshida N, Ota K, Moroi M, Matsuda M. An apparently higher molecular weight γ-chain variant in a congenital abnormal fibrinogen Tochigi characterized by the replacement of γ arginine-275 by cysteine. Blood 1988; 71: 480-7.
28 De Jong WW, Zweers A, Cohen LH. Influence of single amino acid substitution on electrophoretic mobility of sodium dodecyl sulfate-protein complexes. Biochem Biophys Res Commun 1978; 82: 532-9.
29 Noel D, Nikaido K, Ames GF. A single amino acid substitution in a histidine-transport protein drastically alters its mobility in sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Biochemistry 1979; 18: 4159-65.
30 Varadi A, Scheraga HA. Localization of segments essential for polymerization and for calcium binding in the gamma-chain of human fibrinogen. Biochemistry 1986; 25: 519-28.
31 Nieuwenhuizen W, Voskuilen M, Vermond A, Haverkate F, Hermans J. A fibrinogen fragment D (D intermediate) with calcium binding but without anticlotting properties. Biochem Biophys Acta 1982; 707: 190-2.
32 Yee VC, Pratt KP, Côté CF, Le Trong IL, Chung DW, Davie EW, Stenkamp RE, Teller DC. Crystal structure of 30 kDa C-terminal fragment from the γ-chain of human fibrinogen. Sructure 1997; 5: 125-38.
33 Niewenhuizen W, Gravesen M. Anticoagulant and calcium-binding properties of high molecular weight derivatives of human fibrinogen produced by plasmin (fragments X). Biochim Biophys Acta 1981; 668: 81-8.
34 Crabtree GR, Kant JA. Organization of the rat γ-fibrinogen gene. Alternative mRNA splice patterns produce the γA and γB (γ’) chains of fibrinogen. Cell 1982; 31: 159-66.
35 Strong DD, Moore M, Cottrel BA, Bohonus VL, Pontes M, Evans B, Riley M, Doolittle RF. Lamprey fibrinogen γ-chain: Cloning cDNA sequencing, and general characterization. Biochemistry 1985; 24: 92-01.
36 Laudano AP, Doolittle RF. Influence of calcium ion on the binding of fibrin amino terminal peptides to fibrinogen. Science 1981; 212: 457-9.